BioMarin to acquire Huxley Pharmaceuticals

10/26/2009 | American City Business Journals

BioMarin Pharmaceutical will acquire Huxley Pharmaceuticals in a deal that would give BioMarin access to amifampridine phosphate, a treatment for an autoimmune disease called Lambert-Eaton myasthenic syndrome. BioMarin will pay $15 million initially and up to $43.5 million more as milestones are met.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX